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Summary 
Overexpression of the tyrosine kinase receptor ErbB2 is a typical feature of 
many carcinomas, in particular breast cancer where it is associated with 
progression of malignancy, and is a sign of a poor prognosis. Thus, ErbB2 
represents a validated target of therapeutic intervention.  
Herceptin, a humanized anti-ErbB2 antibody, has proved to be very effective in 
the immunotherapy of breast carcinoma. However, some ErbB2-positive 
carcinomas are resistant to Herceptin and it is cardiotoxic in a high percent of 
patients. We have engineered novel fully human immunoagents directed to 
ErbB2. Erbicin, an anti-ErbB2 scFv ; Erb-hRNase, a human immunoRNase 
made up of Erbicin fused to a human RNase; Erb-hcAb, a human, “compact” 
antibody, in which two Erbicin molecules are fused to the CH2 and CH3 
regions of a human IgG1. Both, Erb-hRNase and Erb-hcAb severely inhibit the 
growth of ErbB2-positive cells in vivo.  
To define and implement the antitumor potential of Erbicin, ERB-hcAb, and 
ERB-hRNase, I have deemed essential to gather further and hard data on their 
interactions with ErbB2. The purified antigen was used, i.e. the extracellular 
domain of ErbB2 (ErbB2-ECD), and three different methods of investigation. 
The results provided for the first time a systematic analyses of the binding 
parameters of Erbicin, the Erbicin-Derived-ImmunoAgents (EDIA), in 
comparison with Herceptin. They indicated that the EDIA bind soluble ECD 
with a lower affinity than that of Herceptin, and ErbB2 exposed on the cell 
surface with a higher affinity than that of Herceptin.  
These results suggest that the fraction of immunoagent neutralized by free 
ECD shed into the bloodstream is much higher for Herceptin than for the novel 
immunoagents.  
Finally I show here for the first time that these novel immunoagents recognize 
on the ErbB2 receptor an epitope different from that targeted by Herceptin. 
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Sommario 
L’iperespressione del recettore transmembrana tirosinachinasico ErbB2 
(Her2/neu) è caratteristica di diversi tipi di carcinomi, in particolare del cancro 
della mammella, ed è associata a maggiore aggressività e prognosi infausta. 
ErbB2 rappresenta dunque un bersaglio ideale per l’immunoterapia.  
Herceptin, un anticorpo umanizzato anti-ErbB2 largamente impiegato nella 
terapia del carcinoma mammario, risulta essere cardiotossico per molte 
pazienti. Inoltre molti carcinomi ErbB2-positivi sono resistenti ad Herceptin.  
Basandoci su queste considerazioni nel nostro laboratorio sono stati costruiti 
nuovi immunoagenti (IA) completamente umani anti-ErbB2: Erbicina un scFv 
(single chain variable fragment) anti-ErbB2 costituito dalle regioni variabili 
della catena pesante e leggera dell’anticorpo unite tramite un oligopeptide 
flessibile; Erb-hRNasi, una immunoRNasi costituita dalla fusione di Erbicina 
con la ribonucleasi pancreatica umana (HP-RNasi); hERB-hcAb, un anticorpo 
umano compatto in cui due molecole di Erbicina sono legate alle regioni CH2 e 
CH3 di una IgG1 umana. Entrambi Erb-hRNasi ed Erb-hcAb, risultano essere 
citotossici per cellule ErbB2-positive, inibiscono efficacemente la crescita di 
tumori ErbB2 positivi in vivo e studi preliminari in vitro hanno dimostrato che 
tali IA non presentano effetti cardiotossici. Allo scopo di definire e sfruttare il 
potenziale antitumorale del frammento anticorpale Erbicina e degli 
immunoagenti da essa derivati è stato necessario procedere alla 
caratterizzazione degli stessi mediante studi sulle interazioni con il dominio 
extracellulare del recettore ErbB2 (ErbB2-ECD) utilizzando per la prima volta 
l’antigene in forma solubile.  
L’attività si è articolata in varie fasi:  
a) clonaggio, espressione e purificazione del dominio extracellulare di ErbB2.  
Per tale fine, la regione comprendente i residui 1-624 di ErbB2-ECD è stata 
stabilmente espressa in cellule eucariotiche 293 e secreta nel mezzo di coltura, 
ErbB2-ECD è stato poi purificato mediante cromatografia di immunoaffinità 
con una resa di circa 10mg/L; 
b) ottenuto l’antigene puro, determinazioni dell’affinità di legame di ErbB2-
ECD con gli IA sono state effettuate in parallelo con Herceptin mediantesaggi 
ELISA, saggi calorimetrici e saggi di risonanza plasmonica di superficie 
(SPR);  
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c) mappa dell’epitopo, riconosciuto dagli immunoagenti su ErbB2, al fine di 
determinare se tali IA, riconoscono epitopi differenti rispetto ad anticorpi 
attualmente utilizzati nella cura dei tumori ErbB2 positivi.  
I risultati ottenuti con i diversi approcci metodologici hanno dimostrato che 
Erbicina e gli IA da essa derivati contrariamente ad Herceptin legano ErbB2-
ECD solubile con minore affinità rispetto a quella determinata con ECD 
inserito in cellule ErbB2-positive. Inoltre si è trovato che mentre il legame di 
ERB-hcAb a cellule ErbB2-positive non è influenzato dalla presenza di ECD 
solubile, quello di Herceptin è fortemente inibito. Ciò rappresenta un vantaggio 
ai fini terapeutici poiché i nuovi IA tendono a legarsi con maggiore affinità al 
dominio extracellulare del recettore ErbB2 nella sua conformazione nativa 
associata alla superficie cellulare, rispetto all’ECD libero nel circolo ematico. 
Questa frazione di ECD, prodotta dal taglio proteolitico di metalloproteasi, 
aumenta quando ErbB2 è iperespresso. L’impiego di IA anti-tumorali con 
minore affinità per ECD solubile permetterebbe l’uso di dosi terapeutiche 
inferiori rispetto a quelle usate per Herceptin. La possibilità di eseguire saggi 
ELISA sandwich e saggi SPR  in cui ErbB2-ECD è riconosciuto sia da 
Herceptin, che da Erbicina o ERB-hRNasi, ha fornito inoltre per la prima volta 
una prova indiretta del fatto che Erbicina e gli IA da essa derivati riconoscono 
un epitopo di ErbB2 differente da quello riconosciuto da Herceptin. Per 
l’identificazione dell’ epitopo, il complesso ERB-hcAb-ECD immobilizzato su 
matrice di agarosio, è stato trattato con proteasi specifiche. La regione dell’ 
antigene in contatto con l’anticorpo protetta dal taglio proteolitico è stata 
identificata mediante analisi di spettroscopia di massa MALDI.  
L’epitopo identificato è compreso nella regione N-terminale del primo dominio 
dell’ECD, una regione differente rispetto a quella identificata per gli anticorpi 
anti-ErbB2 noti. Tale risultato offre la prospettiva che gli immunoagenti 
derivati da Erbicina possano agire con meccanismo differente e pertanto 
possano essere impiegati in alternativa o in associazione con Herceptin con un 
conseguente incremento della loro azione antitumorale. 
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Abbreviations 
 
BSA Albumin from bovine serum 
DMEM Dulbecco modified Eagles medium  
ECD Extracellular domain 
EDIA Erbicin-Derived-ImmunoAgents 
ELISA Enzyme Liked Immuno Sorbant Assay 
ErbB2-ECD Extracellular domain of ErbB2 receptor 
ERB-hcAb Human anti-ErbB2-compact Antibody 
FBS Foetal bovine serum  
Fc CH2 and CH3 regions of a human IgG1 
HP-RNasi Human pancreatic RNase 
HRP Horseradish peroxidase 
IA Immunoagents 
ITC Isothermal titration calorimetry 
PBS Phosphate buffer saline 
PVDF Poly-vinylidene difluoride 
ScFv Single-chain antibody fragment   
SDS Sodium dodecyl sulphate 
SPR Surface plasmon resonance 
TRIS Trishydroxymethylaminomethane 
VH The variable domains of heavy chains  
VL The variable domains of light chains  
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INTRODUCTION 
 
ErbB2 (HER2/neu) is a proto-oncogene of the erbB family of tyrosine kinase 
receptors (1). It encodes the ErbB2 185 kDa transmembrane glycoprotein 
receptor, which comprises an extracellular domain (ECD) and an intracellular 
tyrosine kinase activity (2) (Figure 1). While no natural ligand has been 
identified for this receptor, it has been ascertained that its overexpression is 
associated with various carcinomas, in particular with human breast cancer. As 
ErbB2 overexpression is involved in progression of the malignancy, and is a 
sign of a poor prognosis, (3) recent evidence indicates that ErbB2 amplifies the 
signal provided by other receptors of the ErbB family by heterodimerizing with 
them (4). The important biological role of ErbB2 in the signaling network that 
drives epithelial cell proliferation and transformation together with its 
extracellular accessibility and its overexpression has led to consider ErbB2 as a 
validated target of therapeutic intervention. However, when ErbB2 is 
overexpressed not all the ErbB2 protein is embedded in the membrane of 
malignant cells, as it has been reported that a fraction of the extracellular 
domain of ErbB2 (ErbB2-ECD) is proteolytically removed from the receptor 
and is shed as a soluble protein in the sera of breast cancer patients (5). 
Herceptin (6), a humanized anti-ErbB2 antibody, has proved to be an 
essential tool in the immunotherapy of breast carcinoma. However, some 
ErbB2-positive carcinomas are resistant to the growth inhibitory effect of 
Herceptin (7), while in other patients resistance of malignant cells is induced at 
a later stage in the treatment (8). Furthermore, it has been found that Herceptin 
can engender cardiotoxicity in a significant fraction of treated patients (9, 10). 
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An alternative approach to the use of Herceptin in immunotherapy has been 
promoted, based on 
 
 
 
 
 
 
 
 
Figure 1 
 
Domains organization of ErbB2 receptor: domain I and III (red); domain II e 
IV (green) of the extracellular region; the transmembrane domain and the 
intracellular tyrosine kinase domain are in gray. 
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the administration of Herceptin combined with other anti-ErbB2 antibodies (11, 
12). A prerequisite for this strategy is that the latter antibodies are directed to 
epitopes on ErbB2-ECD different from that recognized by Herceptin. 
Based on these considerations, we have been searching for novel 
immunoagents directed to epitopes different from that recognized by Herceptin, 
with no cardiotoxic side effects, and able to fulfil the therapeutic need of 
Herceptin unresponsive patients.  
This led us to the production of a novel, fully human anti-ErbB2 single-
chain antibody fragment (scFv), isolated from a large phage display library 
through a double selection strategy performed on live cells. This scFv (Figure 
2), named Erbicin (13), specifically binds to ErbB2-positive cells, inhibits the 
receptor autophosphorylation, and is internalized in target cells. Furthermore, 
Erbicin has been used to construct more effective human anti-ErbB2 
immunoagents by two different strategies.  
The first was based on immunoconjugates made up of Erbicin fused with 
an RNase, i.e. a pro-toxin, as the RNase becomes toxic only when Erbicin 
promotes its internalization by target cells. One of these fully human 
immunoconjugates, an immunoRNase (IR), denominated ERB-hRNase 
(Erbicin-human-RNase), was produced by the fusion of Erbicin with human 
pancreatic RNase (14) as shown in Figure 3. The alternative strategy was aimed 
at producing a therapeutic reagent with an increased half-life, a prolonged tumor 
retention, and the ability to recruit host effector functions. Erbicin was thus 
fused to the CH2, CH3, and hinge regions from a human IgG1 to obtain an 
immunoglobulin-like antibody (15, 16). 
 10 
 
                             
Figure 2 
 
Schematic representation of Erbicin an anti-ErbB2 single chain variable 
fragment (scFv). VH and VL, the variable domains of heavy and light chains 
respectively; LINKER, the 15-residue junction peptide, (His)6, a 6-residue His 
tag. 
 
                     
Figure 3 
 
Schematic representation of the human immunoRNase ERB-hRNase. VH and 
VL, the variable domains of heavy and light chains respectively, of Erbicin the 
anti-ErbB2 single chain variable fragment (scFv); LINKER, the 15-residue 
junction peptide; SPACER, the peptide connecting Erbicin and the HP-RNase 
moieties and (His)6, a 6-residue His tag. 
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The engineered antibody was called ERB-hcAb (human anti-ErbB2-compact 
Antibody) for its “compact” size (100 kDa), compared with the full size (155 
kDa) of a natural IgG (Figure 4). 
Both Erbicin-Derived-Immunoagents were found to selectively and 
strongly kill ErbB2-positive cells, both in vitro and in vivo (13-16). However, 
to define and implement the antitumor potential of Erbicin, ERB-hcAb, and 
ERB-hRNase, I have deemed essential to gather further and hard data on their 
interaction with ErbB2 by using the purified antigen, i.e. the extracellular 
domain of ErbB2.  
 The majority of antibodies so far isolated from combinatorial libraries 
expressed on phages have been selected using purified antigens, or peptides 
immobilized on artificial surfaces. The disadvantage of this approach is that it 
may lead to the selection of antibodies that do not recognize the antigen in its 
native state within the cell membrane, i.e. in its physiological context (17). On 
the other hand, direct panning of an scFv library on live cells, as it was 
performed for the isolation of Erbicin (13), has the potential of isolating phage 
antibodies that recognize cell surface antigens in their native configuration. 
 To determine and quantitatively evaluate the affinity for ErbB2 of the 
Erbicin and Erbicin-Derived-ImmunoAgents (EDIA), I have used for the first 
time the recombinant extracellular domain of ErbB2 as a homogenous, soluble 
antigen. 
Furthermore, three different analytical methods were employed, and the results 
obtained with Erbicin and the Erbicin-Derived-ImmunoAgents were compared 
with the results obtained with Herceptin. 
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Figure 4 
 
Schematic representation of ERB-hcAb (C), the human compact anti-ErbB2 
antibody made up of two Erbicin molecules (B) fused to the CH2 and CH3 
regions of a human IgG1 (A).  
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All three methodological approaches led to convergent affinity values, which 
de facto validates the results as obtained. Furthermore, we determined and 
compared the affinity values of Herceptin and the Erbicin-Derived-
ImmunoAgents for the ECD structured within the whole receptor molecule, 
natively inserted into the cell membrane, with the values measured using the 
isolated ECD. I found that the Erbicin-Derived-ImmunoAgents bind soluble 
ECD with a lower affinity than Herceptin. On the other hand, the EDIA bind 
ErbB2 exposed on the cell surface with a higher affinity than that of Herceptin 
(14, 15). These results suggest that the fraction of immunoagent neutralized by 
the free ECD shed into the bloodstream is much higher for Herceptin than for 
the novel immunoagents. 
Finally, I report that these novel immunoagents recognize on the ErbB2 
receptor an epitope different from that targeted by Herceptin (18). 
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Materials and Methods 
 
Cell lines and Antibodies 
 
The 293 cell line (human embryonic kidney), was cultured in DMEM (Gibco 
Life Technologies, Paisley, UK BRL). The SKBR3 cell line (human breast 
cancer), was cultured in RPMI 1640 (Gibco BRL). The media were 
supplemented with 10% heat-inactivated foetal bovine serum (FBS), 50 
Units/ml penicillin, and 50 µg/ml streptomycin (all from Gibco). All the cell 
lines were obtained from ATCC (Rockville, MD) and cultured at 37°C in 5% 
CO2 atmosphere. 
The antibodies used were: Herceptin (Genentech, South San Francisco, CA, 
USA); horseradish peroxidase-conjugated anti-His antibody (Qiagen, Valencia, 
CA, USA); horseradish peroxidase-conjugated goat anti-human affinity isolated 
IgG1 (Fc- specific, Sigma, St Louis, MO, USA). Erbicin, ERB-hcAb and ERB-
hRNase were prepared as previously described (13-15). 
 
Production of the extracellular domain of ErbB2 receptor (ErbB2-ECD) 
 
ErbB2-ECD, the extracellular domain of ErbB2 (residues 1–624) was stably 
expressed and secreted by 293 cells. In brief, cells grown in DMEM containing 
10% FBS at 70-80% confluency were co-transfected with 5µg of expression 
vector pVij-hECDopt, coding for the cDNA of ErbB2-ECD, and 100ng of 
selectable plasmid Signal pIg1plus (R & D System, Minneapolis, USA) using 
the SuperFect reagent (Qiagen).  
 15 
Stable transfectants were selected in the presence of G418 (Sigma) at 
concentration of 1mg/mL and subcloned. The expression of ErbB2-ECD was 
evaluated by 8% SDS-PAGE analyses of conditioned medium, under non-
reducing condition, followed by electroblotting onto poly-vinylidene difluoride 
membranes (Millipore Corporation, Bedford, MA, USA). For detection, 
Herceptin was used as primary anti-ErBb2 antibody, followed by horseradish 
peroxidase-conjugated anti-human IgG1 (Fc-specific) mAb for visualization by 
enhanced chemioluminescence (Super signal West Pico, Pierce Rockford, IL, 
USA). The culture medium of 293 cells before transfection was used as negative 
control. For recombinant protein production, co-transfected 293 cells were 
expanded to near confluence in selective medium containing neomycin 
(SIGMA) at concentration of 0,4mg/mL, and then grown for 3-4 days in serum-
free medium. The conditioned medium (1 liter), with an estimated ErbB2-ECD 
concentration about 20 mg/L, was concentrated by ultrafiltration on AMICON 
membranes to 100mL and frozen at -80°C for further processing. 
 
Immunoprecipitation assays 
 
The ErbB2-ECD immunoprecipitation assays were carried out by incubation of 
10 mL aliquots of 293 cells conditioned medium with 10 µg/ml (final 
concentration) of Herceptin or ERB-hcAb in PBS for 3 h at 4°C. The immune 
complexes were then collected by adsorption to protein A-Agarose (Sigma) for 
1 h at 4°C. After washes with PBS, the proteins were released by boiling in 
loading buffer (19), and run on 8% SDS-PAGE, followed by Coomassie 
staining and immunoblotting assays as described above. 
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Protein purification  
 
ErbB2-ECD secreted by transfected 293 cells was purified from culture medium 
by immunoaffinity chromatography with the AKTA Purifier system (GE 
Healthcare, Amersham Bioscience AB, Uppsla, Sweden). The affinity column 
was prepared by coupling 8 mg of Herceptin to 1.5 g of CNBr-activated 
Sepharose 4B Fast Flow (GE Healthcare). The antibody was immobilised to the 
agarose via secondary amine according to the manufacturer’s instructions. The 
resulting 4-ml column was loaded with 10 mL of the concentrated conditioned 
medium, washed with 3 volumes of 10 mM Tris-HCl, pH 7.4 and eluted with 50 
mM Glycine pH 3.0 containing 1M NaCl. The collected fractions were 
immediately neutralized with a 1/10 volume of 1 M Tris-HCl pH 8.0.  
The purity of the preparation was evaluted by 8% SDS-PAGE, followed by 
Coomassie staining and Western Blotting analyses with either Herceptin or 
ERB-hcAb as anti-ErbB2 antibodies, followed by horseradish peroxidase-
conjugated anti-human IgG1 (Fc-specific) mAb. The purified protein was stored 
until use at –20°C after addition of glycerol at a concentration of 10%.  
 
ELISA assays for the complex of ErbB2-ECD and Erbicin or ERB-hRNase 
 
The affinity of Erbicin and ERB-hRNase for soluble ErbB2-ECD was measured 
by an ELISA sandwich assay. A 96-well plate was coated with 5 µg/ml of 
Herceptin in PBS (Sigma), kept overnight at 4°C and blocked for 1 h at 37 °C 
with 5% bovine serum albumin (BSA) (Sigma) in PBS. To the plate rinsed with 
PBS, a solution of purified ErbB2-ECD in PBS (5 µg/ml) was added.  
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After 1 h at room temperature, the plate was washed and increasing 
concentrations of purified ERB-hRNase or Erbicin (50-500 nM) were added in 
ELISA buffer (PBS/BSA 1%) in triplicate wells, and incubated for 2 h at room 
temperature with a blank control of PBS. After rinsing with PBS, an anti-His 
HRP-conjugated antibody was added at 1/1000 dilution in ELISA buffer. After 
1 h at room temperature, the plate was rinsed with PBS, and bound 
immunoagents were detected by using 3,3’,5,5-tetramethylbenzidine (TMB) as 
a substrate (Sigma). The product was measured at 450 nm using a microplate 
reader (Multilabel Counter Victor 3, Perkin Elmer, Cologno Monzese, Italy). 
The reported affinity values are the mean of at least three determinations 
(standard deviation ≤ 5%). 
 
ELISA assays for the complex of ErbB2-ECD and ERB-hcAb or Herceptin 
 
The affinity of ERB-hcAb and Herceptin for ErbB2-ECD was measured as 
follows. A 96-well plate was coated with 5 µg/ml of purified ECD in PBS and 
left overnight at 4°C. After blocking with 5% BSA as above, increasing 
concentrations of ERB-hcAb (10-60 nM) or Herceptin (0.1-10 nM) were added 
in ELISA buffer and allowed to bind for 2 h at room temperature. The plate was 
rinsed with PBS and an anti-human IgG1 (Fc-specific) HRP-conjugated 
antibody was added at 1/1000 dilution in ELISA buffer for antibody detection. 
After 1 h, the plate was rinsed with PBS and bound ERB-hcAb or Herceptin 
was detected as described above.  
 
 
 18 
ELISA assays with ErbB2-positive cells  
 
ELISA assays with ErbB2-positive cells were carried out on SKBR3 cells 
harvested in non-enzymatic dissociation solution (Sigma), washed and 
transferred to U-bottom 96-well microtiter plates (2 x 105 cells per well). After 
blocking with PBS containing 6% BSA, cells were treated with ERB-hcAb or 
Herceptin at increasing concentrations (1-8 nM) in ELISA buffer (PBS/BSA 
3%) in the presence or absence of soluble ErbB2-ECD. ErbB2-ECD was added 
either in equimolar amounts or in a 10-fold molar excess to the ErbB2 receptor 
number on SKBR3 cells (20). After an incubation of 90 minutes at room 
temperature, centrifugation and removal of supernatants, pelleted cells were 
washed twice with ELISA buffer and incubated with peroxidase-conjugated 
anti-human IgG1 (Fc-specific) mAb for antibodies detection. After 1 h, the 
plates were centrifuged, washed with ELISA buffer, and reacted with TMB as 
above. Binding values were determined from the absorbance at 450 nm, and 
reported as the mean of at least three determinations (standard deviation ≤ 5%). 
 
Isothermal titration calorimetry (ITC) 
 
ITC measurements were carried out in collaboration with Prof. C. Giancola, 
Department of Chemistry, Federico II University, Napoli, Italy, as described in 
previous reports (20). In brief, tritrations were performed using a CSC 4200 
calorimeter from Calorimetry Science Corporation (CSC, Utah) with a cell 
volume of 2 mL (Figure 5).  
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Figure 5 
 
Schematic representation of the ITC instrument. 
 
The concentration of the immunoagents (Erbicin, ERB-hRNase, ERB-hcAb), 
in the instrument cell, were 30 µM, and ErbB2-ECD ligand concentration in 
the syringe was 3 µM. For each titration, 10 µL aliquots of ErbB2-ECD in PBS 
solution were injected into the immunoagents solution in PBS at 400 s intervals 
allowing for complete equilibration. Binding curves involved the addition of 
about 25-injections. The heat of dilution of the immunoagents into the solvent 
was measured in a separate experiment and appropriate corrections were made. 
The data were integrated, corrected for dilution heats, normalized for 
concentration, and analyzed, assuming a model based on a single set of 
identical independent binding sites, with the Bindwork software supplied with 
the instrument, which provided a stoichiometry of binding (n ligand:protein), 
change in enthalpy (∆H), and binding constant (Kb).  
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For the experiments with immunoagents binding directly to ErbB2-positive 
cells, SKBR3 cells were grown to half-confluency, left overnight in the 
absence of serum, and collected from the plate by cell dissociation solution. 
After equilibration in a binding buffer made up of PBS containing 3% BSA, 
2.5x105 cells, corresponding to 0.83 pMol of ErbB2 receptor (21) were diluted 
to 2 mL in binding buffer and introduced in the sample cell of the instrument. 
The immunoagents solutions in PBS were added by successive injections as 
above for a total of 1.66 pMol. Data were treated as described above for the 
experiments with soluble proteins. In the experiments in which cell endocytosis 
was blocked, cells were treated, before their introduction in the apparatus 
sample chamber, with 2-deoxy-glucose (50 mM) and Na azide (10 mM) for 2 h 
at 37oC. 
 
Surface plasmon resonance (SPR) analyses 
 
Surface plasmon resonance (SPR) analyses were performed at 25°C on a 
BIAcore X instrument (BiacoreAB, Uppsala, Sweden), equipped with 
research-grade CM5 sensor chips (Biacore). The running buffer was HBS-EP 
buffer (10 mM Hepes, 0.15 M NaCl, 3.4 mM EDTA and 0.005% surfactant 
P20 at pH 7.4). Coupling reagents, N-hydroxysuccinimide (NHS), 1-ethyl-3-
(3-dimethyl aminopropyl) carbodimide hydrochloride (EDC), ethanolamine 
hydrochloride and HBS-EP running buffer were purchased from Biacore 
(Uppsala, Sweden). Soluble carboxymethyl-dextran was from Fluka (Buchs 
SG, Switzerland) and Protein A from Staphylococcus aureus was purchased 
from GE Healthcare (Bio-Sciences). 
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Kinetic analyses by SPR of soluble ErbB2-ECD binding to captured ERB-hcAb 
or Herceptin  
 
SPR analyses were carried out in collaboration with Valeria Cafaro Doctor, 
Department of Structural and Functional Biology, Federico II University, 
Napoli, Italy. To investigate the binding properties of Herceptin and ERB-
hcAb to the soluble extracellular domain of the ErbB2 receptor (ErbB2-ECD), 
a capturing method was chosen. Herceptin and ERB-hcAb were captured by 
Protein A from Staphylococcus aureus immobilized onto the surface of a CM5 
sensor chip using standard amine coupling chemistry. The surface of the chip 
was activated with 70 µL of a mixture 1:1 of 0.4 M 1-ethyl-3-(3-dimethyl 
aminopropyl) carbodimide hydrochloride (EDC) and 0.1 M N-
hydroxysuccinimide (NHS), followed by 100 µL of Protein A (70 µg/ml) 
dissolved in 10 mM sodium acetate buffer, pH 4.5, at a constant flow-rate of 10 
µL/min. Typically, 5000 response units (RU) of Protein A were captured. To 
block unreacted activated esters, 70 µL of 1 M ethanolamine hydrochloride, pH 
8.5, were injected. Non-covalently associated Protein A was washed from the 
surface using four 30-s injections of 10 mM glycine–HCl, pH 2.2. The 
reference flow cell was inactivated by amine coupling chemistry as already 
described, but omitting the Protein A injection. Herceptin (2 µg/mL) or ERB-
hcAb (1 µg/mL) diluted in HBS-EP buffer was injected onto the chip at a flow 
rate of 30 µL/min, giving typically a response of 800-1200 RU for Herceptin 
and 100-200 RU for ERB-hcAb, depending on the contact time. ErbB2-ECD 
diluted in HBS-EP buffer at concentrations of 10-950 nM was passed over the 
immobilized antibodies at a constant flow rate of 30 µL/min, and association 
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and dissociation phases were recorded for 200 s and 300-600 s, respectively. 
The sensor surface was regenerated by 30-s injections of 10 mM Glycine–HCl, 
pH 2.2, at the end of each binding cycle. A blank curve in which only running 
buffer was passed over the captured antibodies was subtracted from each 
sensorgram.  
 
Kinetic analyses by SPR of Erbicin and ERB-hRNase binding to immobilized 
ErbB2-ECD 
 
To measure the binding properties of Erbicin and ERB-hRNase to ErbB2-ECD, 
the ECD was immobilized onto the surface of sensor chip CM5 using standard 
amine coupling chemistry (see above). Carboxymethylated dextran on the 
sensor surface was activated with a 1:1 mixture of EDC and NHS. ErbB2-ECD 
was diluted in 10 mM sodium acetate,  pH 4.5, at a final concentration of 1 
µg/mL, and 60 µL were then applied to the activated carboxymethylated 
dextran surface to capture typically 500 RU of ErbB2-ECD. After 
immobilization, the remaining esters were deactivated with ethanolamine. The 
sensor surface was washed with four 30-s injections of 10 mM NaOH to 
remove unbound ErbB2-ECD. The reference flow cell was activated and 
inactivated by amine coupling chemistry as described above.  
Binding curves were recorded injecting Erbicin (5-700 nM) or ERB-hRNase 
(3–700 nM) over the immobilized ErbB2-ECD at a constant flow rate of 
30µL/min. Association and dissociation phases were recorded for 200 s and 
300 s, respectively. At the end of each detection, the sensor surface was 
regenerated by injecting 10 µL of 10 mM NaOH.  
 23 
For the analysis, each sensorgram was subtracted from the response of the 
surface on which only running buffer was passed over. A second set of binding 
curves was recorded for ERB-hRNase in the presence of soluble 
carboxymethyl-dextran at a final concentration of 5 mg/mL.  
 
Evaluation of kinetic and affinity constants from sensorgram data 
  
The rate constants of the interactions as described above were calculated by a 
non-linear analysis of the association and dissociation curves using the SPR 
kinetic evaluation software package BIAevaluation 3.2 (BIAcore), fitting to the 
1:1 Langmuir binding model. Values of χ 2 for fittings were ≤0.8, indicating 
good fits. The equilibrium dissociation constants (KD) were calculated from the 
values of association rate constant, ka, and dissociation rate constant, kd, 
according to the thermodynamic relationship: KD = kd/ka. Standard deviations 
were obtained from three independent analyses using different biosensors, 
sample preparations, and ligand densities on the flow cell surfaces. 
 
Determination by SPR of apparent affinity constants for Herceptin and ERB-
hcAb binding to the immobilized ErbB2-ECD 
 
Herceptin or ERB-hcAb were passed over ErbB2-ECD immobilized to a CM5 
sensor chip made up as described above. Herceptin (0.16-300 nM) or ERB-
hcAb (0.7-350 nM), diluted in HBS-EP buffer, were injected at 5 µL/min.  
The equilibrium responses for each concentration were determined by 
subsequent injections of the analytes over the chip.  
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The equilibrium responses were plotted versus analyte concentrations and the 
apparent equilibrium constants (KD) were calculated from the concentration 
corresponding to half-maximal saturation. 
 
Determination by SPR of competition in binding to ErbB2-ECD between 
Herceptin and ERB-hcAb or ERB-hRNase  
 
ErbB2-ECD was immobilized to the surface of sensor chip as described above. 
The binding of ERB-hcAb and ERB-hRNase to ErbB2-ECD immobilized on 
the surface were performed by two subsequent injections of 213 nM ERB-
hcAb (corresponding to 426 nM binding site concentration) or 500 nM Erb-
hRNase using a 2 min contact time for each injection at a constant flow rate of 
5 µl/min. The concentrations of ERB-hcAb and ERB-hRNase were chosen 
after several experiments at different concentrations. The sensor chip surface 
was regenerated by a 30 s injection of 25 mM NaOH/1M NaCl.  
Competition in binding to ECD between Herceptin and ERB-hcAb or ERB-
hRNase was investigated by saturating the sensor chip with Herceptin and 
injecting over the surface ERB-hcAb or ERB-hRNase. To this purpose two 
subsequent injections of 440 nM Herceptin at a constant flow rate of 5 µl/min 
were performed using 2 min contact time for each injection, followed by two 
subsequent injections of 213 nM ERB-hcAb or 500 nM ERB-hRNase using a 2 
min contact time for each injection. No regeneration of sensor surface was 
made between injections. 
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Epitope Mapping 
 
Aliquots of ERB-hcAb (800µg) were immobilized on to 400µL of CNBr-
activated Sepharose (GE Healtcare), as described above. Following the 
blocking of the unreacted groups with 1 M ethanolamine hydrochloride, the 
resin was washed with PBS and  ErbB2-ECD (400µg) in PBS was added to the 
resin containing the immobilized ERB-hcAb. Binding of the antigen was 
performed at 4°C while gently rotating overnight.  
The cleavage of antigen-antibody complex with trypsin or endoproteinase Glu-
C (SIGMA) was performed with a E/S ratio of 1/10 for 1 h. Following 
proteolysis, a 10uL aliquot of the beads was removed for direct analyses by 
mass spectrometry (MALDI). Mass spectrometry analyses were carried out in 
collaboration with Prof. P. Pucci, CEINGE Advanced Biotechnology and 
Department of Organic Chemistry and Biochemistry, Federico II University, 
Napoli, Italy, as described in previous reports (22).  
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Results 
 
1.1 Production and characterization of ErbB2-ECD 
 
The cDNA coding for the extracellular domain of ErbB2 receptor (ErbB2-
ECD) was stably transfected in 293 cells. The encoded protein was expressed 
as a secretion product into the culture medium, as revealed by western blotting 
(Figure 6) and immunoprecipitation analyses performed (see Methods) with 
ERB-hcAb or Herceptin as anti-ErbB2 antibodies (see Figure 7A). The final 
yield of ErbB2-ECD purified by affinity chromatography (see Methods) was 
12 mg/L of medium. The protein was analyzed by SDS-PAGE followed by 
Coomassie staining and Western blotting with Herceptin or ERB-hcAb (Figure 
7B). Its molecular size was about 80 kDa, as expected. 
 
 
 
                                     
 
Figure 6 
 
Western Blot analyses of conditioned 293 transfected cells medium with 
Herceptin as an anti-ErbB2-ECD antibody  
Lane 1 negative control (non-transfected 293 cells conditioned medium) 
Lane 2, 3, 4 conditioned medium of different selected clones.  
  1       2          3          4   
   80 kDa 
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Figure 7 
 
(A) Immunoprecipitation analyses of ErbB2 ECD from conditioned 293 cells 
medium with ERB-hcAb (lane 1) or Herceptin (lane 2). Immune complexes 
were evaluated by Western blotting with anti-ErbB2 antibody (Herceptin); (B) 
SDS-PAGE analyses of purified ErbB2-ECD, Lane 1, standards; Lane 2, ECD 
eluted from the immunoaffinity chromatography stained with Coomassie Blue; 
Lanes 3-4, Western blot analyses of the sample as in line 2 using ERB-hcAb or 
Herceptin, respectively, as anti-ErbB2-ECD antibody.  
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1.2 Analyses by ELISA of the interactions of Erbicin, Erbicin-Derived-
ImmunoAgents and Herceptin with ErbB2-ECD 
 
ELISA sandwich assays were performed to determine the ability of Erbicin and 
ERB-hRNase to recognize ErbB2-ECD. Herceptin fixed on the microplate was 
used to capture ErbB2-ECD, which in turn could interact with the anti-ErbB2 
immunoagents. A peroxidase-conjugated anti-His mAb was used to reveal the 
bound immunoagents. 
 The affinity of ERB-hcAb or Herceptin for ErbB2-ECD was instead 
measured by ELISA directly on ECD coated wells. Antibody binding was 
detected with a peroxidase-conjugated anti-human, Fc-specific IgG1 mAb. 
 The results are tabulated in Table I as apparent binding constants, 
measured from the binding curves, shown in Figure 8, as the concentrations 
corresponding to half-maximal saturation.. The obtained values (see Table I) 
were found to be higher than previously reported values (14, 15), obtained 
directly with ErbB2-positive cells, hence with ErbB2 inserted in cell membrane. 
This is an indication of lower affinities of the novel immunoagents for ECD. 
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Figure 8 
 
Binding curves of : (A) ERB-hRNase, (B) Erbicin, (C) ERB-hcAb, (D) 
Herceptin to ErbB2-ECD obtained by ELISA assays. 
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These results appear to be of special interest, as the lower binding 
affinity of Erbicin-Derived-ImmunoAgents for soluble ErbB2-ECD is not 
shared by Herceptin, which displays a high affinity for soluble ErBb2-ECD 
(0.1 nM), about 50-fold higher than that determined when Herceptin was tested 
with ErbB2-ECD embedded in live cells (see Table I). These findings can be 
explained by considering that parental Erbicin was selected from a phage 
library by using ErbB2-ECD inserted into ErbB2-positive cells, whereas for the 
isolation of Herceptin free, soluble ECD was used (23). 
Another interesting indication stems from the results of the ELISA 
sandwich type of assays with Herceptin as a capturing agent. They indicate that 
Erbicin and the novel immunoconjugates (ERB-hRNase, ERB-hcAb) recognize 
on ErbB2-ECD epitopes different from that selected by Herceptin.  
This conclusion is in line with recent data from our laboratory (18). 
Thus, we tested whether soluble ErbB2-ECD could interfere with the binding 
to ErbB2-positive cells of anti-ErbB2 antibodies by performing ELISA with 
 
TABLE I 
 
 
 
ErbB2-ECD 
 
ErbB2-positive 
cells (14, 15) 
 
 
KD apparent 
(nM) 
KD apparent 
(nM) 
Erbicin 
 
50 5 
ERB-hRNase 
 
30 4.5 
ERB-hcAb 
 
7 1 
Herceptin 
 
0.1 5 
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ERB-hcAb or Herceptin in the presence or absence of free ECD. Each antibody 
was tested at increasing concentrations with soluble ECD added either in 
equimolar amounts, or in a 10-fold molar excess to the number of receptor 
molecules on the cell membrane (21). In a parallel experiment, binding was 
assayed in the absence of added ErbB2-ECD. The binding of antibodies was 
detected with a peroxidase-conjugated anti-human, Fc-specific IgG1 mAb.  
As shown in Figure 9A, when ERB-hcAb was tested the binding curves 
obtained in the presence or absence of soluble ECD were found to be 
superimposable. This suggested that the binding ability of ERB-hcAb to ErbB2-
positive cells was unaffected by the presence of soluble ECD. The binding 
instead of Herceptin to ErbB2-positive cells (Figure 9B) was strongly reduced 
by ECD used at a 1:1 ratio with the receptor number, and fully inhibited with a 
10-fold molar excess of ECD. 
These results, in line with those described above on the high affinity of 
Herceptin for soluble ECD, indicate that for Herceptin there is a favourable 
competition of soluble ErbB2-ECD over the ECD on the cell membrane, 
whereas there is no detectable competition by free ECD in the case of ERB-
hcAb.  
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Figure 9 
 
Binding curves of ERB-hcAb (A) or Herceptin (B) to SKBR3 cells obtained 
through ELISA assays performed in the absence (empty symbols) or in the 
presence of soluble ECD. Soluble ECD was added at a ratio of 1:1 with the 
number of receptor molecules on cell membrane (black squares ) or at a ratio of 
10:1 (black circles). 
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1.3 Analyses by Isothermal Titration Calorimetry (ITC) of the interactions of 
Erbicin, Erbicin-Derived-ImmunoAgents and Herceptin with soluble ErbB2- 
ECD  
 
Figure 10 shows the results of a binding study carried out by calorimetric 
titrations of soluble ErbB2-ECD with Erbicin, EDIA and Herceptin. 
Exothermic heat pulses were observed after each injection of the immunoagent 
into the ErbB2-ECD solution (see insets of Fig 10). Integration of the heat 
produced upon injections as a function of time, and conversion to per-mole of 
ErbB2-ECD gives binding isotherms. The data were plotted as a function of 
molar ratio. The stoichiometry of binding (n), binding constants (Kb) and 
enthalpy changes (∆bH°) were obtained from the fitted curves. The Gibbs free 
energy change (∆bG°) and the entropy change (∆bS°) were calculated from the 
equation, 
∆bG° = -RT ln Kb = ∆bH° -T∆bS°  
The obtained thermodynamic parameters are summarized in Table II. 
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Figure 10 
 
Calorimetric titrations for the interaction of the immunoagents with ErbB2-
ECD 
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 Their inspection reveals that the binding stoichiometry is 1:1 also for 
the complexes with the bivalent antibodies ERB-hcAb and Herceptin. 
 As shown by the ∆bH° values, binding is driven by a favourable binding 
enthalpy, opposed by unfavourable binding entropy change, ∆bS°.  
 It is of interest that Erbicin shows the lowest affinity for ErbB2-ECD 
among the studied systems, in agreement with ELISA and SPR results (see 
Tables I and IV). This indicates a greater number of non-covalent interactions 
(H-bonds, van der Waals contacts and salt bridges) upon binding of ECD to 
immunoagents with more stable complexes likely due to cooperation by the 
non-immune moieties. 
When we attempted to study the interactions of the immunoagents with 
live cells, i.e. with ErbB2 inserted on cell membrane, surprising results were 
obtained. The ∆bH° values were about 100-fold higher than those measured 
with soluble receptor, and the binding constants were about 1000-fold higher. 
The possibility that these findings could be attributed not to the binding events, 
but to the internalization process was excluded, as when we tested an anti-
ErbB2 antibody which is not internalised (N28) identical result were obtained.  
Table II n Kb 
(M-1) 
KD 
(nM) 
∆bH 
(kJ mol-1) 
T∆bS 
(kJ mol-1) 
∆bG 
(kJ mol-1) 
ECD/Erbicin 1.0 1.4x107±0.2 77±10 -300±18 -260±4 -40±6 
ECD/ERB-
hRNase 
1.0 4.8x107±0.6 21±3 -139±8 -95±3 -44±6 
ECD/ERB-
hcAb 
1.0 2.4x108±3 4±0.5 -183±11 -135±2 -48±6 
ECD/Herceptin 1.0 8.4x107 12±1 -94±6 -49±5 -45±5 
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This conclusion was confirmed when we tested cells poisoned to inhibit 
endocytosis (see Table III).  
 
 
 
 
 Apparently, the interactions of anti-ErbB2 immunoagents with 
ErbB2 on live cells cannot be interpreted as simple ligand-to-receptor 
interactions. It has been anticipated in recent reports that ligand binding to cell 
receptors may trigger higher order events in the membrane of targeted cells. In 
these events directly stimulated receptors and other seemingly unrelated 
receptors and effectors are engaged in the formation of complex networks and 
receptor mosaics (24), and may induce membrane bending and remodelling 
(25).  
Table III n Kb/1010 
(M-1) 
KD 
(pM) 
∆bH/105 
(kJ mol-1) 
∆bG 
(kJ mol-1) 
ErbB2-cells/ 
Erbicin 
 
1.6 
 
6.2±0.7 
 
16±2 
 
-1.15±0.07 
 
-62±0.3 
ErbB2-cells/ 
ERB-hRNase 
 
1.1 
 
5.9±0.9 
 
17±2 
 
-3.20±0.05 
 
-61.±9 
ErbB2-cells/ 
ERB-hcAb  
 
1.2 
 
27.7±1.9 
 
3.6±0.2 
 
-1.20±0.03 
 
-65.±4 
ErbB2-cells/ 
Herceptin 
 
1.0 
 
7.5±0.8 
 
13±1 
 
-1.46±0.07 
 
-62±7 
ErbB2-cells/N28 
 
1.0 
 
11.0±5.2 
 
9±4 
 
-1.55±0.09 
 
-63.0±30 
ErbB2-cells 
poisoned/ERB-
hRNase 
 
1.0 
 
4.7±0.9 
 
21±4 
 
-1.85±0.04 
 
-61±12 
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An ErbB signalling network has been proposed (26) after an analysis at the 
systems level, with ErbB2 as an amplifier of the network (27). Thus antibody 
binding, which mimics ligand binding, may set off events beyond binding, 
which are evidenced by an incredibly higher binding affinity and a high heat 
production.  
 
1.4 Analyses by Surface Plasmon Resonance (SPR) of the interactions of ERB-
hcAb and Herceptin with soluble ErbB2-ECD 
 
To compare the binding properties of ERB-hcAb and Herceptin to soluble 
ErbB2-ECD with a different methodology based on physico-chemical 
principles, SPR analyses were carried out. Herceptin and ERB-hcAb are 
bivalent molecules, each endowed with two identical antigen binding sites. 
Hence, a kinetic binding study by SPR was carried out by capturing the 
antibodies with Protein A covalently immobilized onto the surface of a sensor 
chip, and by passing soluble ErbB2-ECD (a monovalent analyte) over the chip 
surface (see Methods).  
Figure 11 shows the binding curves recorded for determining the 
association and dissociation rate constants for ERB-hcAb (A) and Herceptin 
(B) complexes with ErbB2-ECD. These analyses highlighted completely 
different kinetic behaviours for the two antibodies. 
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Figure 11 
Sensorgrams recorded of ErbB2-ECD binding to ERB-hcAb (A), Herceptin 
(B),Erbicin (C), ERB-hRNase (D). 
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Herceptin bound ErbB2-ECD with a relatively low ka value of 7.25 x 103 M-1 
sec-1, about 3-fold lower than the value determined for the ERB-hcAb complex 
(1.77 x 104 M-1 sec-1). As for the dissociation step, the Herceptin/ErbB2-ECD 
complex was found to be much more stable, with a kd of 6.5 x 10-5 sec-1, about 
one order of magnitude lower than the kd value of the ERB-hcAb/ErbB2-ECD 
complex (4.35 x 10-4sec-1).  
The calculated equilibrium dissociation constant (KD) for 
Herceptin/ErbB2-ECD and ERB-hcAb/ErbB2-ECD 1:1 complexes were 9.4 
and 24.7 nM per binding site, respectively. These data indicated that Herceptin 
binds to soluble ErbB2-ECD with a higher affinity than ERB-hcAb, so that 
Herceptin is strongly sequestered into the immuno-complex. They are in line 
with those reported above and obtained with ELISA (see Table I), but the KD 
values 9.4 nM and 24.7 were higher than the apparent constants (half-maximal 
saturation concentrations) measured with ELISA for the same complexes (0.1 
and 7 nM, respectively).  
These large differences could however be ascribed to the different 
experimental system used for the ELISA and the SPR binding assays.  
The system was thus investigated by SPR with a different experimental 
set up, similar to that used for ELISA (see above), based on ErbB2-ECD 
covalently immobilized on the chip surface, with Herceptin or ERB-hcAb 
injected over the chip. Half-maximal saturation values were measured and 
found to be 11 nM for ERB-hcAb/ErbB2-ECD and 0.13 nM for 
Herceptin/ErbB2-ECD.  
These values (see Table IV) are in good agreement with the data 
obtained with the ELISA assays reported above (7 and 0.1 nM, respectively).  
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The conclusion can hence be drawn that the differences in affinity values 
obtained with the kinetic study are essentially due to the different modes of 
interaction of bivalent antibodies. When the antibodies are immobilized 
through Protein A on the SPR chip, each antigen binding site can interact with 
a free ECD molecule in a 1:1 complex. When instead it is ECD to be 
immobilized onto the SPR chip, both antibody binding sites can interact with 
ECD. Binding of antibody to the first site will increase the chances of collision 
and binding at the second site, but dissociation from the second site does not 
release easily the antibody from the adsorbed antigen. This is in line with the 
findings of low kd values for the dissociation of the antibodies complexes as 
determined by kinetic SPR analyses. 
 
 
 
TABLE IV 
 
ka (M-1 sec-1) a 
 
kd (sec-1) a 
 
 
KD (nM) a 
 
KD  
apparent 
(nM) 
 
Erbicin  
 
1.33 ±0.13 x105 
 
6.16 ±0.42 x 10-3 
 
46.7 ±0.55 
 
 
 
Erb-hRNase 
 
1.5 ±0.18 x 105 
 
4.12 ±0.84 x 10-3 
 
27.2 ±0.25 
 
 
 
Erb-hRNase b  
 
1.61 x 105 
 
4.47 x 10-3 
 
27.8 
 
 
 
ERB-hcAb 
 
1.77 ±0.13 x1 04 
 
4.35 ±0.09 x 10-4 
 
24.7 ±0.24 
 
9.24 
 
Herceptin 
 
7.25 ±2.4 x 103 
 
6.5 ±1.12 x 10-5 
 
9.4 ±0.15 
 
0.13 
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1.5 SPR analyses of Erbicin and ERB-hRNase binding to ErbB2-ECD 
 
We investigated by SPR the interactions with soluble ErbB2-ECD of the 
single-chain fragment (Erbicin) and its RNase conjugate (ERB-hRNase). 
Binding was measured with ErbB2-ECD covalently immobilized onto a sensor 
chip, while Erbicin or ERB-hRNase were flowed across the chip. The kinetic 
constants were obtained for these monovalent analytes through fitting the 
curves with a 1:1 interaction model. Similar binding curves were obtained with 
Erbicin and ERB-hRNase (see Figure 11 C and D), showing very similar 
association rate constants, but slightly different dissociation rate constants (see 
Table IV). Erbicin, with a kd value of 6.16 x 10-3 sec-1, dissociated from ErbB2-
ECD 1.5 times faster than ERB-hRNase (kd = 4.12 x 10-3 sec-1).  
This indicated a higher stability for the ERB-hRNase/ErbB2-ECD 
complex. Equilibrium KD values were 46.7± 5 and 27.2 ± 3.3 nM, respectively, 
for Erbicin/ErbB2-ECD and Erb-hRNase/ErbB2-ECD, as tabulated in Table 
IV. The significant difference in KD values could be clearly ascribed to the 
different, lower dissociation rate constant measured for the ERB-
hRNase/ErbB2-ECD complex. These data, in good agreement with those 
obtained from the ELISA experiments reported above (50 and 30 nM, 
respectively), can be ascribed, as suggested above, to interactions with the non 
immune moieties, in particular to aspecific electrostatic interactions between 
the positively charged RNase linked in the immunoconjugate and the 
negatively charged carboxymethyl-dextran matrix of the SPR chip. Thus, the 
kinetic analyses of the ERB-hRNase/ErbB2-ECD complex were repeated in the 
presence of soluble carboxymethyl-dextran.  
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However, identical constants were measured for the ERB-hRNase/ErbB2-ECD 
complex in the presence or absence of soluble carboxymethyl-dextran (Table 
IV). This indicates that the higher stability of ERB-hRNase/ErbB2-ECD 
complex was not due to aspecific ionic interaction, but to specific structural 
features of immunoagent-ErbB2-ECD complex.  
 
1.6 ErbB2-ECD epitope recognized by Erbicin-Derived-ImmunoAgents (EDIA) 
is different from that Herceptin 
 
To determine if the novel immunoagents recognize an epitope different from 
that targeted by Herceptin, competition experiments were carried out by 
plasmon resonance assays of EDIA binding in the presence of Herceptin. In 
these experiments, ERB-hcAb and ERB-hRNase were each injected over 
ErbB2-ECD immobilized on the chip, before and after saturation with 
Herceptin (Figure 12). After the ErbB2-ECD surface was saturated by repeated 
injections of Herceptin until no significant additional response was observed 
(Figure 12), equivalent molar amounts of each immunoagent were injected.  
 The binding curves obtained for ERB-hcAb and ERB-hRNase were 
found to be identical to those obtained in the absence of Herceptin (Figure 12, 
insets). This indicates that each immunoagent could bind to the ECD on the 
chip surface irrespective of the previous saturation with Herceptin.  
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Figure 12 
Binding of ERB-hcAb (A) and ERB-hRNase (B) to the ErbB2-ECD 
immobilized on plasmon resonance chips, before or after their saturation with 
Herceptin. From left to right: ECD saturated with Herceptin by two subsequent 
injections (marked by arrows) before the addition of either ERB-hcAb (A) or 
ERB-hRNase (B) by two subsequent injections (marked by arrows) over the 
chip. The insets show the binding of ERB-hcAb (A) or ERB-hRNase (B) to the 
ECD in the absence of Herceptin.  
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In conclusion, the novel immunoagents do not compete with Herceptin for 
binding to ErbB2, hence they bind an epitope different from that of Herceptin. 
To identify the epitope recognized by Erbicin and EDIA, ErbB2-ECD 
was coupled to the ERB-hcAb antibody previously immobilized on Sepharose 
beads. The immobilized antigen-antibody complex was subjected to proteolysis 
with endoproteinase Glu-C and trypsin. The peptide segments protected within 
the antibody/ECD complex indicate that the epitope is contained within the 
first domain of ErbB2-ECD (Figure 13). These results confirm that the novel 
immunoagents (Erbicin, ERB-hRNase, ERB-hcAb) recognize a different 
epitope on ErbB2-ECD from that of Herceptin and other available anti-ErbB2 
monoclonal antibodies such as Pertuzmab, 7c2 and MAB74 (28, 18).  
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RSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGS 
180 
 
 181 
RCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSG2 
40 
 
 241 
ICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEV 
300 
 
 301 
TAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFD 
360 
 
 361 
GDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYS 
420 
 
 421 
LTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPED 
480 
 
 481 
ECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLP 
540 
 
 541 
CHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGA 
600 
 
 601  
CQPCPINCTHSCVDLDDKGCPAEQRASPLT 
 
 
 
 
Figure 13 
In red, the peptide segments of ErbB2 recognized by Erbicin and EDIA. 
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Conclusions 
 
The novel antitumor immunoagents Erbicin, ERB-hcAb and ERB-hRNase 
have most, potentially all, the features which can make an immunoagent a 
valid, precious tool for anti-cancer immunotherapy: 1. they are all of human 
origin, which would seriously decrease, if not eliminate, the risks of immune 
response; 2. they are directed to a cell receptor, such as ErbB2, minimally 
present in non-malignant cells, but over-expressed in many carcinomas, 
especially in breast cancer cells; 3. they selectively kill ErbB2-positive cells, 
both in vitro and in vivo; 4. their size, smaller than that of immunoglobulins, 
should favour penetration in solid tumors; however, in the case of ERB-hcAb 
and ERB-hRNase, it should also allow for a prolonged half-life in the 
bloodstream.  
 Binding to a cell-embedded tumor-associated-antigen is the first key 
step in the mechanism of antitumor immunoagents. Thus, I directed my 
attention to studying the binding properties not only of the novel Erbicin-
derived anti-ErbB2 immunoagents, but also of Herceptin, an immunoagent 
successfully employed in the therapy of breast cancer. Furthermore, the 
availability of soluble ErbB2-ECD has led us to describe for the first time the 
binding of these immunoagents to the isolated, free extracellular domain of 
ErbB2. Also for the first time the binding study was conducted not only with a 
semi-quantitative methodology, such as that based on ELISA, the only 
methodology previously used for measuring Herceptin binding (15), but also 
with quantitative methods based on physico-chemical principles, such as 
surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC). 
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 The main results of this study can be summarized as follows. 
1. For the first time extensive and conclusive information are reported on 
relative affinity and binding kinetics of the Erbicin-Derived-ImmunoAgents 
and Herceptin for soluble, or cell-linked ErbB2. 
2. The results are validated through the use of three independent 
methodologies: ELISA, SPR, and ITC, which gave coherent results.  
3. The binding of Erbicin to ErbB2-ECD was found to be enhanced and 
stabilized through the linking of the Erbicin scFv to either an RNase or the Fc 
antibody fragment, as in ERB-hRNase and ERB-hcAb, respectively. This was 
revealed by the higher binding affinity of the Erbicin immunoconjugates with 
respect to that of the free Erbicin scFv.  
4. The novel, Erbicin-Derived-ImmunoAgents display a binding affinity 
towards soluble ErbB2-ECD lower than that measured for ECD embedded in 
the membrane of ErbB2-positive cells. Herceptin instead shows a higher 
affinity for soluble ErbB2-ECD. Furthermore, binding of ERB-hcAb to cancer 
cells is not affected by soluble ECD, whereas that of Herceptin is strongly 
inhibited. As soluble ECD is proteolytically released from the surface of 
ErbB2-overexpressing cancer cells, and is detected in the serum of patients 
with advanced breast cancer (5), a fraction of Herceptin is neutralized in these 
patients by serum ECD, hence it is subtracted to cell-directed antitumor action 
(29). 
Thus, the data inserted in this thesis indicate that EDIA, the Erbicin-
Derived-ImmunoAgents have a superior therapeutic potential with respect to 
Herceptin, as their use. 
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5. I reported here for the first time that the epitope recognised by the Erbicin 
based immunoagents is different from that targeted by Herceptin (2).  
This observation is supported by results from two different types of tests: 
plasmon resonance analyses (18) and mass spectroscopic analyses.  
6. A binding study carried out by ITC on anti-ErbB2 immunoagents tested 
directly on live cells has revealed that the association of the immunoagents to 
the receptor inserted into live cells cannot be interpreted as a simple ligand-to-
receptor interaction. Apparently, antibody binding, just like ligand binding, 
triggers higher order events which engage other membrane receptors and 
effectors in the formation of complex networks and receptor mosaics. 
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